ABSTRACT: Introduction: We report the reliability of a new measure, the triple-timed up-and-go (3TUG) test, for assessing clinical function in patients with Lambert-Eaton myasthenia (LEM). Methods: Intrarater reproducibility and interrater agreement of the 3TUG test were assessed in 25 control participants, 24 patients with non-LEM neuromuscular disease, and 12 patients with LEM. The coverage probability (CP) method was the primary measure of reproducibility and agreement. The a priori acceptable range was < 20% difference in 3TUG test times and a CP 0.90 confirmed agreement. Results: CP values > 0.90 for intrarater and interrater tests confirmed acceptable reproducibility and agreement for all groups. Discussion: The 3TUG test is a quick, noninvasive, and reproducible measure that is easy to perform, measures clinically important weakness in LEM patients, and requires little training. Additional evaluation in a larger number of LEM patients is in progress to validate the 3TUG test as a clinical measure in LEM.
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Muscle Nerve 57: [136] [137] [138] [139] 2018 No single outcome measure has been used or observed to quantify the functional disability in Lambert-Eaton myasthenia (LEM). Timed up-andgo (TUG) tests measure the time it takes a participant to rise from a chair, walk a short distance, and return to the chair; these tests have been used mainly to assess mobility in Parkinsonism and in the elderly. [1] [2] [3] Their test-retest reproducibility is high (intraclass correlation of 0.985-0.988, P < 0.001), and it has been suggested that a change of even 3.5 4 -4 5 s or 29.8% 4 may represent a clinically significant change.
The 3TUG test was developed to provide a simple, noninvasive measure of disease severity in patients with LEM, who typically have weakness in thigh and hip girdle muscles that causes difficulty walking, climbing stairs, and rising from a chair. To assess the potential effect on the TUG of neuromuscular fatigue or facilitation, which are characteristic of LEM, the 3TUG test consists of 3 laps performed as follows: The participant is seated in a standard 18-in.-high straight-backed armchair. The floor 3 meters from the front legs of the chair is marked with a line of colored tape, and the center of the line is marked with an "X." Participants are instructed to get up from the chair, walk at their normal pace to the line, step on the X, turn around, walk back to the chair, turn around, and sit down. This is repeated 3 times without rest. Each lap ends when the participant's back contacts the chair back and the patient is instructed to begin the next lap or informed that the test is complete. The 3TUG test time is the average of the 3 lap times.
The 3TUG test was successfully used as an entry criterion and as the primary outcome measure in a recently completed prospective clinical trial of 3,4-diaminopyridine free base (DAP) in LEM, the DAPPER study. 6, 7 To evaluate further the 3TUG test for clinical use, we undertook to assess its reproducibility and agreement when measured by different examiners and when repeated by the same examiner.
MATERIALS AND METHODS
This study was approved by the Duke University institutional review board for clinical investigations, and all participants provided informed consent for their participation.
Participants and 3TUG Test Procedures. Study participants consisted of 25 controls (adults with no history of neuromuscular disease or other difficulty walking) and 24 patients with a non-LEM neuromuscular disease. To minimize the risk of falls during 3TUG testing, patients were excluded from Additional supporting information may be found in the online version of this article Abbreviations: 3TUG, triple-timed up-and-go; CP, coverage probability; DAP, 3,4-diaminopyridine free base; DAPPER, prospective trial of 3,4-diaminopyridine free base in Lambert-Eaton myasthenia; LEM, LambertEaton myasthenia; NMD, neuromuscular disease Key words: 3,4-diaminopyridine; coverage probability; Lambert-Eaton myasthenia; outcome measures; reliability; timed up-and-go test Funding: Research reported in this publication was supported, in part, by the National Center for Advancing Translational Sciences, National Institutes of Health (Grant No. UL1TR001117). Dr Guptill is supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health (Grant No. K23NS085049). The DAPPER trial was sponsored by Jacobus Pharmaceutical Co (JPC), which provided 3,4-diaminopyridine free base for the LEM patients in this study. Conflicts of Interest: Dr Sanders is a paid consultant to Jacobus Pharmaceutical Co (JPC). Drs Ale s and Jacobus are employees of JPC. Dr Juel was site investigator for the DAPPER trial, which was sponsored by JPC. The remaining authors have no conflicts of interest to disclose. Correspondence to: D. B. Sanders; e-mail: donald.sanders@duke.edu participation in the study if they reported that they had fallen within the preceding 3 months or if they or their doctor believed that there was any physical risk to performing the 3TUG test. The enrolled participants first performed 3 laps without timing to minimize the effect of learning, followed by a timed trial (test 1), a 5-min rest period, and a second timed trial (test 2). All testing was performed with the same assistive device, if any, that the participant normally used at that time of day. Both 3TUG tests were recorded with a video camera placed to capture the full length of the walking course. (A) Controls. Data from 75 paired 3TUG test times measured by 2 live observers and 1 blinded observer on 25 control participants. All test-retest differences are less than 1.25 s, and 71/75 are within 6 1.96 SD of the mean. The measurement for test 1 was, on average, 0.13 s greater than that for test 2. (B) Neuromuscular disease. Data from 72 paired 3TUG test times for test 1 and test 2 measured by 2 live observers and 1 blinded observer on 24 patients with non-LEM neuromuscular disease. All test-retest differences are less than 2 s, and 67/72 are within 6 1.96 SD of the mean. The measurement for test 1 was, on average, 0.22 s greater than that for test 2. (C) LEM. Data from 24 paired 3TUG test times for day 0 and day 1 from a live observer and a blinded observer on 12 patients with LEM. All test-retest differences are less than 2 s, and 22/24 are within 6 1.96 SD of the mean. The measurement for test 1 was, on average, 0.42 s greater than that for test 2. 3TUG, triple-timed up-and-go; LEM, Lambert-Eaton myasthenia; NMD, neuromuscular disease.
Laps were timed "live" independently by 2 observers; one observer read the instructions for the first test and the other observer did so for the second test. Laps were also timed from the video by an independent observer who was blinded to the live readings and the order in which the 3TUG tests had been performed.
Data were also obtained from the live and blind-recorded readings of 3TUG tests performed by 12 LEM patients during the baseline observation phase of the DAPPER study, during which they were taking a constant dose of DAP.
6 3TUG test times obtained on 2 consecutive days at the same time of day and interval after DAP were compared.
Data Analysis. Intrarater (test-retest) reproducibility was assessed in all 3 cohorts by comparing each participant's 3TUG test time for test 1 with their time for test 2 as measured by each observer. Interobserver agreement was assessed in all 3 cohorts by comparing the times recorded by each observer with the times of the other observers (e.g., observer A vs. observer B; A vs. C; and B vs. C).
The coverage probability (CP) method was used as the primary assessment of reproducibility and agreement. 8 CP is the probability that the difference between 2 paired observations is within a pre-established acceptable range. The CP is calculated as the number of observed differences within the acceptable range divided by the total number of comparisons; a CP of 1.0 indicates 100% agreement between the observations. Confidence intervals for the CP were calculated by using a binary generalized linear mixed model to account for the correlated outcomes.
Based on reported characteristics of the TUG test in non-LEM patients, 1-5 the primary endpoint in the DAPPER trial was predefined as a deterioration of 30% in the 3TUG test upon withdrawal of study drug. 7 For the current study, it was determined a priori, based on the experience of the study neuromuscular physicians, that the acceptable range would be a 20% difference in 3TUG test times and that agreement would be demonstrated by a CP 0.90 (i.e., 90% of all differences are within the acceptable range). 4 The CP method was selected as the primary evaluation because of its simplicity and broad applicability to different patient populations and clinical settings. To estimate precision and to CI, confidence interval; CP, coverage probability; DAPPER, prospective trial of 3,4-diaminopyridine free base in Lambert-Eaton myasthenia; LEM, Lambert-Eaton myasthenia; Min/Max, minimum/maximum; NE, not estimable; NMD, neuromuscular disease. 
CI, confidence interval; CP, coverage probability; DAPPER, prospective trial of 3,4-diaminopyridine free base in Lambert-Eaton myasthenia; LEM, LambertEaton myasthenia; Min/Max, minimum/maximum; NE, not estimable; NMD, neuromuscular disease.
guide the enrollment targets for the control participants and neuromuscular disease patients, 95% binomial confidence intervals for a CP 5 0.90 were calculated at various sample sizes. Bland-Altman plots of test-retest results were produced to provide visual validation of the agreement data (Fig. 1) . 9 In these plots, differences on the y-axis are plotted against averages on the x-axis to confirm the CP agreement assessments.
RESULTS
Intrarater (Test-Retest) Reproducibility. For intrarater reproducibility results (test-retest), see Table 1 . Control Participants. The mean percentage difference between test 1 and test 2 among the 3 observers was 1.54, and none of the pairs exceeded a 20% difference, giving a CP of 1.0 and demonstrating agreement (Supporting Information Table  1 ). A Bland-Altman plot (Fig. 1A) confirms the CP agreement assessment.
Neuromuscular Disease Patients. Among the 24 participants with a non-LEM neuromuscular disease, 16 had myasthenia gravis, 5 had CharcotMarie-Tooth disease, 1 had CIDP, and 2 had myotonic dystrophy type 1. The mean percentage difference between the 2 tests among the 3 observers for the 72 pairs was 1.90, and none of the differences exceeded 20%, again giving a CP of 1.0 and demonstrating agreement (Supporting Information Table 2 ) A Bland-Altman plot (Fig. 1B) confirms the CP agreement assessment.
DAPPER LEM Patients. Among the 12 LEM patients, the mean 3TUG test time on day 0 was 9.37 s, and on day 1 it was 8.96 s. The difference exceeded 10% in 5 of 24 pairs and exceeded 20% in 2 pairs, resulting in a CP of 0.92, which is above the preestablished threshold of 0.90 for acceptable agreement (Supporting Information Table 3 ). A Bland-Altman plot (Fig. 1C) confirms the CP agreement assessment.
Interrater Agreement. The average difference in 3TUG test times measured by different observers was very small in all 3 groups. The percentage difference did not exceed 20% (or even 10%) for any of the pairs, resulting in a CP of 1.0 in all groups (Table 2) .
DISCUSSION
The 3TUG test was developed to be a measure of dysfunction that could be used to identify patients with LEM who benefit from DAP. This study demonstrates that the 3TUG test has excellent agreement among independent observers, that within-subject reproducibility is excellent in control participants and in a selected group of patients with non-LEM neuromuscular disease, and that agreement and reproducibility are acceptable in a small group of patients with LEM. The results also indicate that the 3TUG test can be reliably scored from video recordings, making it suitable for clinical trials with a central reader. The use of 3 repetitions of the TUG was based on concern that neuromuscular fatigue or facilitation could affect LEM patients to different degrees and thus potentially adversely affect the ability of the test to determine the effect of treatment among patients with different levels of disease severity.
The 3TUG test is a quick, noninvasive, reliable, and reproducible measure that is easy to perform, measures clinically important weakness in LEM patients, and requires little training. Based on these characteristics, the 3TUG test was selected as the primary outcome measure for the DAPPER trial of DAP in LEM and to predict responsiveness of patients in that trial. 6, 7 The expected variability in 3TUG test time in patients with LEM on stable doses of medication is <20%. Additional evaluation in a larger number of LEM patients with different levels of severity is in progress to confirm this, to determine the value of 3 repetitions, and to validate the 3TUG test as a clinical measure in LEM.
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